Physiomics PLC - oncology consultant - Says awarded further contracts of undisclosed value with clients Bicycle Therapeutics PLC and Merck KGaA. "The project with Bicycle is the eighth signed with this high-profile UK biotech company, spanning four different assets within its pipeline, and involves population pharmacokinetic analysis of clinical data from one of these assets," Physiomics says.
"The project with Merck is an extension of one of the projects previously announced for calendar year 2020 in what is now the third year of work under the Master Services Agreement announced in November 2017."
Current stock price: 6.78 pence
Year-to-date change: up 97%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)